阿巴西普单药与联合治疗类风湿关节炎相关间质性肺病的多中心研究
该回顾性多中心研究纳入263例高加索裔RA-ILD患者,比较阿巴西普单药与联合MTX或非MTX传统合成DMARDs的疗效与安全性。结果显示三组在FVC、DLCO、呼吸困难、胸部HRCT及DAS28-ESR方面无显著差异,但仅联合治疗组观察到激素节约效应。
要点
- 阿巴西普单药或联合csDMARDs对RA-ILD患者疗效与安全性相当。
- 仅联合阿巴西普组观察到显著的激素节约效应。
- 三组间FVC、DLCO、呼吸困难及HRCT变化无统计学差异。
核心结论
- 在高加索裔RA-ILD患者中,阿巴西普单药或联合MTX或其他传统合成DMARDs似乎同等有效且安全。
- 激素节约效应仅在联合阿巴西普组中观察到。
研究设计与样本
- 回顾性多中心研究,纳入263例接受阿巴西普治疗的高加索裔RA-ILD患者。
- 分为三组:阿巴西普单药组(n=111)、阿巴西普联合MTX组(n=46)、阿巴西普联合非MTX传统合成DMARDs组(n=106)。
主要发现
- 所有组中多数患者FVC、DLCO、呼吸困难和胸部HRCT稳定或改善,DAS28-ESR改善。
- 仅联合阿巴西普组在基线与末次随访间激素节约效应有统计学显著差异。
- 多变量分析显示三组间任何结局变量均无差异。
关键数值与推荐
- 阿巴西普单药组基线年龄67±10岁,泼尼松剂量10(IQR 5-15)mg/天,高于其他组。
- 基线性别、血清阳性、ILD模式、FVC、DLCO及病程无统计学显著差异。
临床怎么用
- 对于RA-ILD患者,阿巴西普单药或联合csDMARDs均可作为治疗选择,疗效与安全性相当。
- 若需激素节约效应,可考虑阿巴西普联合csDMARDs治疗。
局限性
- 回顾性研究设计可能引入选择偏倚和信息偏倚。
- 仅纳入高加索裔患者,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the efficacy and safety of abatacept (ABA) in monotherapy (ABAMONO) vs combined ABA [ABA plus MTX (ABAMTX) or ABA plus non-MTX conventional synthetic DMARDs (csDMARDs) (ABANON-MTX)] in RA patients with interstitial lung disease (ILD) (RA-ILD). METHODS: This was a restrospective multicentre study of RA-ILD Caucasian patients treated with ABA. We analysed in the three groups (ABAMONO, ABAMTX, ABANON-MTX) the following outcome variables: (i) dyspnoea; (ii) forced vital capacity (FVC) and diffusion capacity of the lung for the carbon monoxide (DLCO); (iii) chest high-resolution CT (HRCT); (iv) DAS28-ESR; (v) CS-sparing effect; and (vi) ABA retention and side-effects. Differences between basal and final follow-up were evaluated. Multivariable linear regression was used to assess the differences between the three groups. RESULTS: We studied 263 RA-ILD patients (mean ± s.d. age 64.6 ± 10 years) [ABAMONO (n = 111), ABAMTX (n = 46) and ABANON-MTX (n = 106)]. At baseline, ABAMONO patients were older (67 ± 10 years) and took higher prednisone dose [10 (interquartile range 5-15) mg/day]. At that time, there were no statistically significant differences in sex, seropositivity, ILD patterns, FVC and DLCO, or disease duration. Following treatment, in all groups, most patients experienced stabilization or improvement in FVC, DLCO, dyspnoea and chest HRCT as well as improvement in DAS28-ESR. A statistically significant difference between basal and final follow-up was only found in CS-sparing effect in the group on combined ABA (ABAMTX or ABANON-MTX). However, in the multivariable analysis, there were no differences in any outcome variables between the three groups. CONCLUSION: In Caucasian individuals with RA-ILD, ABA in monotherapy or combined with MTX or with other conventional-DMARDs seems to be equally effective and safe. However, a CS-sparing effect is only observed with combined ABA.
引用
- Fernández-Díaz C, Atienza-Mateo B, Castañeda S, et al. Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 Caucasian patients. Rheumatology (Oxford). 2021. PMID: 33779697. doi:10.1093/rheumatology/keab317
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。